{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T11:25:57Z","timestamp":1766748357392,"version":"build-2065373602"},"reference-count":77,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","criticalcare.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Care Clinics"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ccc.2021.03.007","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T06:24:56Z","timestamp":1622096696000},"page":"577-589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Toxicology of Medications for Diabetes Mellitus"],"prefix":"10.1016","volume":"37","author":[{"given":"Kevin","family":"Baumgartner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Devgun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ccc.2021.03.007_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.diabres.2009.10.007","article-title":"Global estimates of the prevalence of diabetes for 2010 and 2030","volume":"87","author":"Shaw","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"10.1016\/j.ccc.2021.03.007_bib2","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.2337\/dc13-2289","article-title":"Use of antidiabetic drugs in the U.S., 2003-2012","volume":"37","author":"Hampp","year":"2014","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.ccc.2021.03.007_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/15563650.2017.1337908","article-title":"Non-health care facility medication errors resulting in serious medical outcomes","volume":"56","author":"Hodges","year":"2018","journal-title":"Clin Toxicol (Phila)"},{"issue":"6","key":"10.1016\/j.ccc.2021.03.007_bib4","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.2337\/dci18-0019","article-title":"Insulin access and affordability working group: conclusions and recommendations","volume":"41","author":"Cefalu","year":"2018","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.ccc.2021.03.007_bib5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrendo.2017.39","article-title":"Insulin analogues in type 1 diabetes mellitus: getting better all the time","volume":"13","author":"Mathieu","year":"2017","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"10.1016\/j.ccc.2021.03.007_bib6","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3109\/15563650.2013.829236","article-title":"Demographics and outcome of unintentional insulin overdoses managed by three poison centers","volume":"51","author":"Beuhler","year":"2013","journal-title":"Clin Toxicol (Phila)"},{"issue":"6","key":"10.1016\/j.ccc.2021.03.007_bib7","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/bcpt.12957","article-title":"A\u00a0systematic review on insulin overdose cases: clinical course, complications and treatment options","volume":"122","author":"Johansen","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"10.1016\/j.ccc.2021.03.007_bib8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2169\/internalmedicine.39.55","article-title":"Electrolyte disorders following massive insulin overdose in a patient with type 2 diabetes","volume":"39","author":"Matsumura","year":"2000","journal-title":"Intern Med"},{"issue":"7","key":"10.1016\/j.ccc.2021.03.007_bib9","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1507\/endocrj.K11E-018","article-title":"Prediction of recovery time from hypoglycemia in patients with insulin overdose","volume":"58","author":"Ohyama","year":"2011","journal-title":"Endocr J"},{"issue":"5","key":"10.1016\/j.ccc.2021.03.007_bib10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/00063110-200510000-00007","article-title":"Prolonged hypoglycaemia after insulin lispro overdose","volume":"12","author":"Brvar","year":"2005","journal-title":"Eur J Emerg Med"},{"issue":"4","key":"10.1016\/j.ccc.2021.03.007_bib11","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jemermed.2010.04.007","article-title":"Lantus insulin overdose: a case report","volume":"41","author":"Lu","year":"2011","journal-title":"J\u00a0Emerg Med"},{"issue":"3","key":"10.1016\/j.ccc.2021.03.007_bib12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/15563658909038579","article-title":"Massive insulin overdose: detailed studies of free insulin levels and glucose requirements","volume":"27","author":"Samuels","year":"1989","journal-title":"J\u00a0Toxicol Clin Toxicol"},{"issue":"7","key":"10.1016\/j.ccc.2021.03.007_bib13","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0196-0644(84)80513-2","article-title":"Duration of hypoglycemia and need for intravenous glucose following intentional overdoses of insulin","volume":"13","author":"Stapczynski","year":"1984","journal-title":"Ann Emerg Med"},{"issue":"2","key":"10.1016\/j.ccc.2021.03.007_bib14","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jemermed.2012.11.099","article-title":"Octreotide for the treatment of hypoglycemia after insulin glargine overdose","volume":"45","author":"Groth","year":"2013","journal-title":"J\u00a0Emerg Med"},{"issue":"4","key":"10.1016\/j.ccc.2021.03.007_bib15","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1017\/cem.2017.422","article-title":"Octreotide for the treatment of intentional insulin aspart overdose in a non-diabetic patient","volume":"20","author":"Dewaal","year":"2018","journal-title":"CJEM"},{"issue":"1","key":"10.1016\/j.ccc.2021.03.007_bib16","first-page":"e70","article-title":"Role of steroids in refractory hypoglycemia due to an overdose of 10,000 units of insulin glargine: a case report and literature review","volume":"4","author":"Tariq","year":"2018","journal-title":"AACE Clin Case Rep"},{"issue":"7","key":"10.1016\/j.ccc.2021.03.007_bib17","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/bjs.1800730707","article-title":"Local excision of subcutaneous fat in the management of insulin overdose","volume":"73","author":"McIntyre","year":"1986","journal-title":"Br J Surg"},{"issue":"6346","key":"10.1016\/j.ccc.2021.03.007_bib18","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/bmj.285.6346.974-b","article-title":"Managing suicidal insulin overdose","volume":"285","author":"Levine","year":"1982","journal-title":"Br Med J Clin Res Ed"},{"issue":"3","key":"10.1016\/j.ccc.2021.03.007_bib19","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bcp.12822","article-title":"Treatment of sulfonylurea and insulin overdose","volume":"81","author":"Klein-Schwartz","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.ccc.2021.03.007_bib20","doi-asserted-by":"crossref","first-page":"e0221174","DOI":"10.1371\/journal.pone.0221174","article-title":"National ambulatory care non-insulin antidiabetic medication prescribing trends in the United States from 2009 to 2015","volume":"14","author":"Kitten","year":"2019","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.ccc.2021.03.007_bib21","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3109\/15563650.2014.987397","article-title":"2013 annual report of the American Association of Poison Control Centers\u2019 National Poison Data System (NPDS): 31st annual report","volume":"52","author":"Mowry","year":"2014","journal-title":"Clin Toxicol (Phila)"},{"issue":"7","key":"10.1016\/j.ccc.2021.03.007_bib22","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/0960327106080223","article-title":"Adult glyburide ingestions reported to Texas poison control centers, 1998\u20132005","volume":"26","author":"Forrester","year":"2007","journal-title":"Hum Exp Toxicol"},{"issue":"6","key":"10.1016\/j.ccc.2021.03.007_bib23","doi-asserted-by":"crossref","first-page":"e1558","DOI":"10.1542\/peds.2010-3235","article-title":"Hypoglycemia in pediatric sulfonylurea poisoning: an 8-year poison center retrospective study","volume":"127","author":"Lung","year":"2011","journal-title":"Pediatrics"},{"issue":"12","key":"10.1016\/j.ccc.2021.03.007_bib24","doi-asserted-by":"crossref","first-page":"e231368","DOI":"10.1136\/bcr-2019-231368","article-title":"A\u00a0case of severe relapsing sulphonylurea-induced hypoglycaemia","volume":"12","author":"Mifsud","year":"2019","journal-title":"BMJ Case Rep"},{"issue":"3","key":"10.1016\/j.ccc.2021.03.007_bib25","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0272-6386(00)70204-6","article-title":"Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease","volume":"35","author":"Krepinsky","year":"2000","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.ccc.2021.03.007_bib26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s13181-010-0064-z","article-title":"Octreotide\u2019s role in the management of sulfonylurea-induced hypoglycemia","volume":"6","author":"Dougherty","year":"2010","journal-title":"J\u00a0Med Toxicol"},{"issue":"2","key":"10.1016\/j.ccc.2021.03.007_bib27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1067\/mem.2000.108183","article-title":"Octreotide: an antidote for sulfonylurea-induced hypoglycemia","volume":"36","author":"McLaughlin","year":"2000","journal-title":"Ann Emerg Med"},{"issue":"4","key":"10.1016\/j.ccc.2021.03.007_bib28","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.annemergmed.2007.06.493","article-title":"Comparison of octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia","volume":"51","author":"Fasano","year":"2008","journal-title":"Ann Emerg Med"},{"issue":"9","key":"10.1016\/j.ccc.2021.03.007_bib29","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3109\/15563650.2012.734626","article-title":"Octreotide for the treatment of sulfonylurea poisoning","volume":"50","author":"Glatstein","year":"2012","journal-title":"Clin Toxicol (Phila)"},{"issue":"9","key":"10.1016\/j.ccc.2021.03.007_bib30","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","article-title":"The mechanisms of action of metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.ccc.2021.03.007_bib31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrendo.2013.256","article-title":"Metformin--mode of action and clinical implications for diabetes and cancer","volume":"10","author":"Pernicova","year":"2014","journal-title":"Nat Rev Endocrinol"},{"issue":"11\u201312","key":"10.1016\/j.ccc.2021.03.007_bib32","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1177\/0885066618793385","article-title":"Review of biguanide (metformin) toxicity","volume":"34","author":"Wang","year":"2019","journal-title":"J\u00a0Intensive Care Med"},{"issue":"4","key":"10.1016\/j.ccc.2021.03.007_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002967.pub3","article-title":"Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus","author":"Salpeter","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.ccc.2021.03.007_bib34","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1074\/jbc.275.1.223","article-title":"Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I","volume":"275","author":"El-Mir","year":"2000","journal-title":"J\u00a0Biol Chem"},{"issue":"7","key":"10.1016\/j.ccc.2021.03.007_bib35","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1177\/0960327108090589","article-title":"Adult metformin ingestions reported to Texas poison control centers, 2000-2006","volume":"27","author":"Forrester","year":"2008","journal-title":"Hum Exp Toxicol"},{"issue":"12","key":"10.1016\/j.ccc.2021.03.007_bib36","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1345\/aph.10116","article-title":"Multicenter case series of pediatric metformin ingestion","volume":"34","author":"Spiller","year":"2000","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.ccc.2021.03.007_bib37","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.annemergmed.2009.04.023","article-title":"Acute metformin overdose: examining serum pH, lactate level, and metformin concentrations in survivors versus nonsurvivors: a systematic review of the literature","volume":"54","author":"Dell\u2019Aglio","year":"2009","journal-title":"Ann Emerg Med"},{"issue":"2","key":"10.1016\/j.ccc.2021.03.007_bib38","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/emj.19.2.169","article-title":"Recovery from pH 6.38: lactic acidosis complicated by hypothermia","volume":"19","author":"Ahmad","year":"2002","journal-title":"Emerg Med J"},{"issue":"7","key":"10.1016\/j.ccc.2021.03.007_bib39","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/CCM.0b013e3181a02490","article-title":"Metformin-associated lactic acidosis: a prognostic and therapeutic study","volume":"37","author":"Seidowsky","year":"2009","journal-title":"Crit Care Med"},{"issue":"4","key":"10.1016\/j.ccc.2021.03.007_bib40","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2165\/00002018-199920040-00006","article-title":"Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations","volume":"20","author":"Lalau","year":"1999","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.ccc.2021.03.007_bib41","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s13181-019-00755-6","article-title":"Do patients die with or from metformin-associated lactic acidosis (MALA)? Systematic review and meta-analysis of pH and lactate as predictors of mortality in MALA","volume":"16","author":"Blumenberg","year":"2020","journal-title":"J\u00a0Med Toxicol"},{"issue":"8","key":"10.1016\/j.ccc.2021.03.007_bib42","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1097\/CCM.0000000000001002","article-title":"Extracorporeal treatment for metformin poisoning: systematic review and recommendations from the extracorporeal treatments in poisoning workgroup","volume":"43","author":"Calello","year":"2015","journal-title":"Crit Care Med"},{"issue":"2","key":"10.1016\/j.ccc.2021.03.007_bib43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF01263444","article-title":"Lactic acidosis in biguanide-treated diabetics: a review of 330 cases","volume":"14","author":"Luft","year":"1978","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.ccc.2021.03.007_bib44","doi-asserted-by":"crossref","first-page":"591","DOI":"10.7326\/0003-4819-87-5-591","article-title":"Phenformin-associated lactic acidosis: pathogenesis and treatment","volume":"87","author":"Misbin","year":"1977","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ccc.2021.03.007_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-210229","article-title":"A\u00a0severe case of vasoplegic shock following metformin overdose successfully treated with methylene blue as a last line therapy","volume":"2015","author":"Graham","year":"2015","journal-title":"BMJ Case Rep"},{"issue":"7","key":"10.1016\/j.ccc.2021.03.007_bib46","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/15563650.2016.1180390","article-title":"A\u00a0systematic analysis of methylene blue for drug-induced shock","volume":"54","author":"Warrick","year":"2016","journal-title":"Clin Toxicol (Phila)"},{"issue":"18","key":"10.1016\/j.ccc.2021.03.007_bib47","doi-asserted-by":"crossref","first-page":"16504","DOI":"10.1074\/jbc.M110.208447","article-title":"Alternative mitochondrial electron transfer as a novel strategy for neuroprotection","volume":"286","author":"Wen","year":"2011","journal-title":"J\u00a0Biol Chem"},{"issue":"4","key":"10.1016\/j.ccc.2021.03.007_bib48","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"issue":"6","key":"10.1016\/j.ccc.2021.03.007_bib49","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/dmrr.1202","article-title":"The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review","volume":"27","author":"Aroda","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"issue":"4","key":"10.1016\/j.ccc.2021.03.007_bib50","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/1573399812666151223093841","article-title":"Glucagon-like peptide-1 receptor agonists for type 2 diabetes: a clinical update of safety and efficacy","volume":"12","author":"Drab","year":"2016","journal-title":"Curr Diabetes Rev"},{"issue":"5","key":"10.1016\/j.ccc.2021.03.007_bib51","first-page":"V11140595","article-title":"A\u00a045-fold liraglutide overdose did not cause hypoglycaemia","volume":"177","author":"Madsen","year":"2015","journal-title":"Ugeskr Laeger"},{"issue":"7","key":"10.1016\/j.ccc.2021.03.007_bib52","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/jcph.94","article-title":"10-fold liraglutide overdose over 7\u00a0months resulted only in minor side-effects","volume":"53","author":"Bode","year":"2013","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ccc.2021.03.007_bib53","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.diabres.2012.10.017","article-title":"Attempted suicide with liraglutide overdose did not induce hypoglycemia","volume":"99","author":"Nakanishi","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.ccc.2021.03.007_bib54","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4103\/2452-2473.276386","article-title":"Liraglutide overdose: a case report and an updated review","volume":"20","author":"Nafisah","year":"2020","journal-title":"Turk J Emerg Med"},{"issue":"1","key":"10.1016\/j.ccc.2021.03.007_bib55","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3109\/15563650.2012.752495","article-title":"No clinical harm from a massive exenatide overdose: a short report","volume":"51","author":"Krishnan","year":"2013","journal-title":"Clin Toxicol (Phila)"},{"issue":"S2","key":"10.1016\/j.ccc.2021.03.007_bib56","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1017\/cem.2017.439","article-title":"Intentional overdose of liraglutide in a non-diabetic patient causing severe hypoglycemia","volume":"20","author":"Solverson","year":"2018","journal-title":"CJEM"},{"issue":"3","key":"10.1016\/j.ccc.2021.03.007_bib57","first-page":"28","article-title":"Two lessons from the empiric management of a combined overdose of liraglutide and amitriptyline","volume":"2","author":"Bowler","year":"2014","journal-title":"Case Rep"},{"issue":"1","key":"10.1016\/j.ccc.2021.03.007_bib58","doi-asserted-by":"crossref","first-page":"23055","DOI":"10.3402\/ljm.v9.23055","article-title":"An accidental liraglutide overdose: case report","volume":"9","author":"Elmehdawi","year":"2014","journal-title":"Libyan J Med"},{"key":"10.1016\/j.ccc.2021.03.007_bib59","unstructured":"Payen C, Thouret JM, Vial T, et\u00a0al. Mild hypoglycaemia and delayed effects of co-ingestions following acute exenatide (Bayetta) poisoning. Presented at the 2012 International Congress of the European Association of Poisons Centres and Clinical Toxicologists, 25 May\u20131 June 2012, London, UK."},{"key":"10.1016\/j.ccc.2021.03.007_bib60","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1146\/annurev-physiol-021113-170315","article-title":"Glucagon-like peptide-1: glucose homeostasis and beyond","volume":"76","author":"Cho","year":"2014","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.ccc.2021.03.007_bib61","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-6823-10-7","article-title":"Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes","volume":"10","author":"Williams-Herman","year":"2010","journal-title":"BMC Endocr Disord"},{"issue":"2","key":"10.1016\/j.ccc.2021.03.007_bib62","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s13181-014-0383-6","article-title":"Clinical effects of exposure to DPP-4 inhibitors as reported to the national poison data system","volume":"10","author":"Russell","year":"2014","journal-title":"J\u00a0Med Toxicol"},{"issue":"3","key":"10.1016\/j.ccc.2021.03.007_bib63","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/15563650.2014.889302","article-title":"A\u00a0retrospective review of isolated gliptin-exposure cases reported to a state poison control system","volume":"52","author":"Darracq","year":"2014","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.ccc.2021.03.007_bib64","unstructured":"Whitney IJ, Borys DJ, Morgan DL. Incidence of hypoglycemia in sitagliptin overdose. Presented at the 2009 North American Congress of Clinical Toxicology Annual Meeting, September 21\u201326, 209, San Antonio, Texas, USA."},{"issue":"4","key":"10.1016\/j.ccc.2021.03.007_bib65","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1507\/endocrj.EJ11-0390","article-title":"Suicide attempt by an overdose of sitagliptin, an oral hypoglycemic agent: a case report and a review of the literature","volume":"59","author":"Furukawa","year":"2012","journal-title":"Endocr J"},{"issue":"11","key":"10.1016\/j.ccc.2021.03.007_bib66","first-page":"OD01","article-title":"A\u00a0case of janumet poisoning","volume":"11","author":"Bahulikar","year":"2017","journal-title":"J\u00a0Clin Diagn Res"},{"key":"10.1016\/j.ccc.2021.03.007_bib67","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1038\/ki.2010.512","article-title":"Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans","volume":"120","author":"List","year":"2011","journal-title":"Kidney Int Suppl"},{"issue":"2","key":"10.1016\/j.ccc.2021.03.007_bib68","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/jdi.12401","article-title":"Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors","volume":"7","author":"Ogawa","year":"2016","journal-title":"J\u00a0Diabetes Investig"},{"issue":"12","key":"10.1016\/j.ccc.2021.03.007_bib69","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1016\/j.clinthera.2016.11.002","article-title":"SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis","volume":"38","author":"Goldenberg","year":"2016","journal-title":"Clin Ther"},{"issue":"10","key":"10.1016\/j.ccc.2021.03.007_bib70","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1111\/dom.13811","article-title":"Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: the STOP DKA protocol","volume":"21","author":"Goldenberg","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.ccc.2021.03.007_bib71","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1038\/s41598-017-02733-w","article-title":"Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.ccc.2021.03.007_bib72","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/M19-0085","article-title":"Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases","volume":"170","author":"Bersoff-Matcha","year":"2019","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.ccc.2021.03.007_bib73","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/14740338.2019.1602116","article-title":"An update on the safety of SGLT2 inhibitors","volume":"18","author":"Scheen","year":"2019","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"10.1016\/j.ccc.2021.03.007_bib74","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1080\/15563650.2017.1357824","article-title":"Retrospective review of SGLT2 inhibitor exposures reported to 13 poison centers","volume":"56","author":"Schaeffer","year":"2018","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.ccc.2021.03.007_bib75","unstructured":"Smith K, Gomez L, Smith L, et\u00a0al. How sweet it is: sodium glucose co-transporter 2 inhibitor ingestions reported to U.S. poison centers. Presented at the 2017 North American Congress of Clinical Toxicology, October 11\u201315, 2017, Vancouver, British Columbia, Canada."},{"issue":"1","key":"10.1016\/j.ccc.2021.03.007_bib76","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40360-019-0381-z","article-title":"Severe intoxication caused by sodium-glucose cotransporter 2 inhibitor overdose: a case report","volume":"21","author":"Nakamura","year":"2020","journal-title":"BMC Pharmacol Toxicol"},{"issue":"2","key":"10.1016\/j.ccc.2021.03.007_bib77","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11428-018-0310-6","article-title":"Suizidversuch mit dem SGLT-2-inhibitor Empagliflozin rettet Patientin das Leben","volume":"14","author":"Schneider","year":"2018","journal-title":"Diabetologia"}],"container-title":["Critical Care Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074907042100018X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074907042100018X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T02:08:37Z","timestamp":1760062117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S074907042100018X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S074907042100018X"],"URL":"https:\/\/doi.org\/10.1016\/j.ccc.2021.03.007","relation":{},"ISSN":["0749-0704"],"issn-type":[{"type":"print","value":"0749-0704"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicology of Medications for Diabetes Mellitus","name":"articletitle","label":"Article Title"},{"value":"Critical Care Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccc.2021.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}